The glioblastoma multiforme market is expected to grow at a CAGR of 13.2% from 2026-2036, driven by next-generation therapies entering late-stage development. The market was valued at USD 900 million in 2025 across the 7MM, with approximately 38,000 incident cases. Key players including Avita Biomedical, Kazia Therapeutics, Laminar Pharma, and others are advancing innovative immunotherapies, targeted treatments, and personalized medicine approaches to address the poor prognosis of this aggressive brain tumor.

BrewDog, part of Tilray Brands, is launching a major summer campaign centered around international football, featuring a nationwide 'Win a Year of Beer' promotion with 2.8 million promotional packs across U.K. retailers, destination match-day watch parties at BrewDog bars, and multi-channel activations across retail, e-commerce, and digital platforms.

Tilray Brands has improved its fundamentals with stronger international cannabis sales (73% YoY growth) and reduced net losses, but the stock's breakout potential remains heavily dependent on U.S. cannabis rescheduling and legalization. While the company shows operational progress, other cannabis stocks with broader catalysts may offer better opportunities.

Canopy Growth announced it will restate financial results for two years due to a technical accounting error involving share-settled warrants that should have been classified as liabilities rather than equity. The company states the restatement won't impact revenue, operating income, cash flows, or key performance metrics. However, the stock remains a risky penny stock in a struggling marijuana sector facing intense competition and illicit market pressures. Most investors should avoid the stock until it achieves sustainable profitability and the restatement is complete.

AI adoption is rapidly transforming the cannabis industry, with North American operators deploying advanced technologies for cultivation optimization, retail personalization, and regulatory compliance. Early adopters like PURPLEFARM have demonstrated significant ROI, including a 20% yield increase using AI-powered systems. Major capital deployment and competitive advantages are being gained by well-funded companies implementing AI across cultivation, manufacturing, and retail operations.

While the cannabis beverage market is projected to grow significantly from $7.4 billion to $242.68 billion by 2034, Tilray Brands appears to be a value trap rather than a value opportunity. Despite trading at a low forward price-to-sales ratio of 0.7 and having a strong position in cannabis beverages, the company's poor financial performance, inconsistent revenue growth, and persistent net losses raise concerns. Even if marijuana becomes federally legal in the U.S., Tilray faces intense competition from well-capitalized beverage giants and uncertain prospects.

Tilray stock briefly surged on news of marijuana rescheduling from Schedule I to Schedule III but quickly gave back gains and fell below initial levels. While rescheduling removes some tax burdens, it alone doesn't enable cannabis companies to enter the U.S. market, which requires full federal legalization. Tilray faces persistent headwinds including ongoing losses and poor performance of its cannabis-infused beverages.

While the U.S. rescheduled medical marijuana from Schedule I to Schedule III, this does not equate to legalization. Canadian cannabis producer Tilray Brands claims to be positioned for U.S. expansion, but legalization efforts could take years and are not currently on lawmakers' radar. The article cautions investors against expecting near-term U.S. market entry, noting Tilray's poor stock performance since 2018 and the risks of holding the stock based on speculative legalization hopes.

Roth Capital analyst Bill Kirk upgraded Tilray to 'buy' with a 12-month price target of $10, suggesting over 40% upside based on stable Canadian operations, strong international growth (70% YoY increase), and improving beverages business. However, the author remains skeptical, noting Tilray missed revenue estimates, faces industry headwinds, and a 40% gain would likely require broader cannabis industry recovery. The author suggests cannabis ETFs may offer better diversified exposure.

Tilray Brands announced strategic initiatives including the acquisition of UK-based Lyphe Group to expand its medical cannabis platform, stabilization of BrewDog following its recent acquisition, and launch of Hi*Ball Energy in the UK. The company filed an $180 million at-the-market equity program to fund global beverage expansion and is positioning itself for potential U.S. medical cannabis rescheduling opportunities.

Tilray Brands launched PORTAL, a new high-potency cannabis brand targeting experienced consumers with high tolerance. The brand features liquid diamond vapes and diamond-coated pre-rolls with THC levels of 95-99%, positioning itself as a premium offering in the maturing infused cannabis category. Products are rolling out at select Canadian retailers ahead of 4/20.

Multiple companies are set to report earnings during the holiday-shortened week of March 30, 2026. Key reports include Rezolve AI on Monday, Virgin Galactic and Gorilla Technology on Monday after-hours, Nike on Tuesday after-hours, Tilray Brands on Wednesday, and Nauticus Robotics on Thursday. Nike faces scrutiny over China demand weakness and tariffs, while Virgin Galactic is expected to report continued losses.